Literature DB >> 18335565

Extracorporeal photopheresis: Lighting the way to immunomodulation.

Aleksandar M Babic1.   

Abstract

Photopheresis, initially established as an effective treatment of cutaneous T-cell lymphoma, has in recent years also been used to treat chronic graft vs. host disease, heart transplant rejection, and several other conditions requiring immunosuppression. Despite reported beneficial results of this procedure in treatment of various conditions, randomized controlled clinical trials are lacking for the majority of suggested indications. Furthermore, the mechanisms of action of this procedure are still unclear. Deeper understanding of the molecular basis of photopheresis-based immunomodulation will allow better selection of patients to be treated and will facilitate development of novel, minimally toxic immunomodulatory treatments. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18335565     DOI: 10.1002/ajh.21166

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  8 in total

1.  Rapid generation of maturationally synchronized human dendritic cells: contribution to the clinical efficacy of extracorporeal photochemotherapy.

Authors:  Carole Berger; Kristin Hoffmann; Juan G Vasquez; Shrikant Mane; Julia Lewis; Renata Filler; Aiping Lin; Hongyu Zhao; Tyler Durazzo; Abigail Baird; William Lin; Francine Foss; Inger Christensen; Michael Girardi; Robert Tigelaar; Richard Edelson
Journal:  Blood       Date:  2010-08-18       Impact factor: 22.113

2.  Detection and characterization of soluble CD93 released during inflammation.

Authors:  Mallary C Greenlee; Sarah A Sullivan; Suzanne Slater Bohlson
Journal:  Inflamm Res       Date:  2009-07-15       Impact factor: 4.575

3.  Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.

Authors:  Laura Y McGirt; Christopher Thoburn; Allan Hess; Eric C Vonderheid
Journal:  Photodermatol Photoimmunol Photomed       Date:  2010-08       Impact factor: 3.135

4.  Pathogen-reduced PRP blocks T-cell activation, induces Treg cells, and promotes TGF-β expression by cDCs and monocytes in mice.

Authors:  Johnson Q Tran; Marcus O Muench; Rachael P Jackman
Journal:  Blood Adv       Date:  2020-11-10

5.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

6.  Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood.

Authors:  Rachael P Jackman; Marcus O Muench; Heather Inglis; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2016-11-18       Impact factor: 3.157

Review 7.  Cellular regulation of the inflammatory response.

Authors:  William J Janssen; Peter M Henson
Journal:  Toxicol Pathol       Date:  2011-11-16       Impact factor: 1.902

8.  Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Authors:  Rachael P Jackman; John W Heitman; Susanne Marschner; Raymond P Goodrich; Philip J Norris
Journal:  Transfusion       Date:  2009-08-04       Impact factor: 3.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.